Graph Therapeutics Secures $5M to Advance AI-Powered Precision Immunology Pipeline
核心洞察
Graph Therapeutics (搜索) raised $5 million in new funding led by Daphni (搜索), bringing total funding to over $10 million including non-dilutive grants.
The company's proprietary "lab-in-the-loop" AI platform combines live patient cell models with machine learning to decode immune dysfunction and identify novel drug targets.
Funding will advance internal drug discovery programs across multiple inflammatory and immune-mediated disease indications while expanding platform capabilities.
Graph Therapeutics (搜索), a next-generation techbio company developing precision medicines for inflammatory and immune-mediated diseases (搜索), has secured a $5 million investment led by Paris-based venture capital firm Daphni (搜索). The new capital brings the company's total funding to over $10 million, including equity investments and non-dilutive grant funding from Austrian innovation agencies.
Daphni (搜索) joins Graph's existing investor syndicate, which includes SquareOne (搜索), Merantix Capital (搜索), and NAVEC Investment Management (搜索). The company has also received additional non-dilutive funding from the Austrian Research Promotion Agency (搜索) (FFG) through its Austrian Life Sciences program and from Austria Wirtschaftsservice (搜索) (AWS) via its Deep Tech Life Sciences Seed Financing program.
"Graph's platform has reached a critical inflection point as we are now generating actionable biological insights that directly inform our own drug discovery programs," said Gregory Vladimer, PhD, Co-Founder and CEO of Graph Therapeutics (搜索). "Daphni (搜索)'s conviction in our approach is a powerful signal as we begin to scale investment into asset programs."
A Lab-in-the-Loop Approach to Immune Dysfunction
Graph's proprietary platform combines perturbation modelling of complex live patient samples, functional and multi-omics profiling, and advanced machine learning to decode immune dysfunction at scale. By generating insights directly from real patient tissue rather than simplified model systems, the company identifies disease mechanisms, novel therapeutic targets, and biomarkers that inform the development of differentiated therapies.
The platform has been substantially de-risked and validated across clinically relevant biological models, creating what the company describes as a strong foundation for novel therapeutic programs. Building on the founding team's experience in AI-driven precision oncology at Allcyte — which was acquired by Exscientia — Graph applies a lab-in-the-loop perturbation approach to primary patient cell samples and multi-omics data.
"Graph exemplifies the next generation of techbio: a company where deep technological innovation is inseparable from rigorous R&D, led by a team with a proven track record in precision medicine," said a representative from Daphni (搜索). "The complexity of immune-mediated diseases demands exactly this kind of integrated approach."
Pipeline Advancement and Strategic Opportunities
The new funding will support the advancement of Graph's internal drug discovery pipeline across multiple inflammatory and immune-mediated disease indications, while further expanding the company's platform capabilities. The maturity of the platform also opens opportunities for strategic partnerships and out-licensing initiatives, extending the impact of Graph's technology beyond its internal pipeline.
Graph noted that the non-dilutive grant awards from Austria's innovation agencies reflect independent validation of its scientific approach and highlight Austria's public funding ecosystem for deep tech life sciences companies. With the latest financing, the company aims to demonstrate that rigorously decoding immune dysfunction in real patient cells can reveal what actually drives disease, positioning precision medicines in inflammation and immunology as a tangible near-term goal.